ERBB2 and breast carcinoma: An example in breast cancer is the semi-quantitative assessment of the expression of the human epidermal growth factor receptor 2 (HER2) as determined by immunohistochemistry (IHC) which defines patient eligibility for anti-HER2 therapies.